EDN1 and diabetes mellitus: In CAD patients with renal dysfunction, elevated ET‐1 levels were associated with increased MACE risk (adjusted HR 1.333, 95% CI 1.169–1.519, p < 0.001), with those in the highest group and DM showing a 2.134‐fold (95% CI, 1.334–3.413, p < 0.001) increased MACE risk.